VERRICA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.9 USD | -2.27% |
|
-2.40% | -5.74% |
Financials (USD)
| Sales 2024 * | 23.95M | Sales 2025 * | 72.18M | Capitalization | 293M |
|---|---|---|---|---|---|
| Net income 2024 * | -76M | Net income 2025 * | -39M | EV / Sales 2024 * | 12.2 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.06 x |
| P/E ratio 2024 * |
-4.45
x | P/E ratio 2025 * |
-8.73
x | Employees | 100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on Verrica Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | -2.27% | ||
| 1 week | -2.40% | ||
| Current month | +16.55% | ||
| 1 month | +45.26% | ||
| 3 months | +19.79% | ||
| 6 months | +92.20% | ||
| Current year | -5.74% |
1 week
6.77
7.15
1 month
4.607.32
Current year
4.607.32
1 year
2.867.76
3 years
1.7714.79
5 years
1.7718.67
10 years
1.7723.29
| Managers | Title | Age | Since |
|---|---|---|---|
Ted White
CEO | Chief Executive Officer | 59 | 17-11-30 |
Terence Kohler
DFI | Director of Finance/CFO | 46 | 21-07-15 |
| Compliance Officer | 60 | 18-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Prygocki
BRD | Director/Board Member | 58 | 18-04-30 |
Paul Manning
CHM | Chairman | 68 | 15-11-30 |
Craig Ballaron
BRD | Director/Board Member | 63 | 19-06-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 6.9 | -2.27% | 202,527 |
| 24-04-17 | 7.06 | +0.86% | 105,357 |
| 24-04-16 | 7 | +1.16% | 89,905 |
| 24-04-15 | 6.92 | +0.73% | 163,836 |
| 24-04-12 | 6.87 | -2.83% | 184,162 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.9
USD
Average target price
13.6
USD
Spread / Average Target
+97.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.74% | 299M | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- VRCA Stock
